Caribou Biosciences Inc
CRBUHealthcare|Biotechnology|USA
$1.93
-0.01 (-0.77%)
Tangible Book
$1.05
About
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Stock Price
+10.6%(1Y)
Pipeline Summary
5 total trials4
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 1Unknown: 1ENROLLING_BY_INVITATION: 1Terminated: 1Withdrawn: 1
Active Trials (1)
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
NCT05722418Relapsed/Refractory Multiple Myeloma
Phase 1Recruiting
Enrollment: 50 participants
BioScore
4.4/10
Cautious
Ownership
Recent Insider Trades
Kelly Timothy PSELL
2026-02-256,228 shares @ $1.93
Kelly Timothy PSELL
2026-02-243,147 shares @ $1.96
MCCLUNG BARBARA GSELL
2026-02-246,938 shares @ $1.96
Khan Ruhi AhmadSELL
2026-02-246,938 shares @ $1.96
Albertson Tina M.SELL
2026-02-241,066 shares @ $1.96
Recent News
2026-06-17 20:00:30
Data last updated: Jul 13, 2026, 12:49 PM